Summary

On 11 March 2020, the World Health Organization declared COVID-19 a global pandemic, and the disease now affects nearly every country and region. Caused by SARS-CoV-2, COVID-19 continues nearly 18 months later to present significant challenges to health systems and public health in both hemispheres, as well as the economies of every country. The morbidity and mortality of the infection caused by SARS-CoV-2 has been significant, and various waves of disease outbreaks initially overwhelmed many hospitals and clinics and continue to do so in many countries. This influences everyone, and public health countermeasures have been dramatic in terms of their impact on employment, social systems, and mental health. This entry collection aims to gather diverse fields about COVID-19, including in epidemiology, public health, medicine, genetics, systems biology, informatics, data science, engineering, sociology, anthropology, nursing, environmental studies, statistics, and psychology.

Expand All
Entries
Topic Review
Humanitarian Activities against COVID-19 Disruption
The COVID-19 pandemic has affected more than 214 countries across the world, disrupting the supply of essential commodities. As the pandemic has spread, humanitarian activities (HAs) have attempted to manage the various situation but appear ineffective due to lack of collaboration and information sharing, inability to respond towards disruption, etc. Developing a sustainable humanitarian supply chain (HSC) for managing disasters/emergencies can be viewed as an extension of the traditional supply chain. Thus, sustainable HSCs have evolved as a specialized discipline with a focus on social sustainability. 
  • 1.2K
  • 12 Apr 2023
Topic Review
Extracellular Vesicles for COVID-19
COVID-19 is an infectious disease caused by the novel coronavirus (SARS-CoV-2) that first appeared in late 2019 and has since spread across the world. It is characterized by symptoms such as fever, cough, and shortness of breath and can lead to death in severe cases. To help contain the virus, measures such as social distancing, handwashing, and other public health measures have been implemented. Vaccine and drug candidates, such as those developed by Pfizer/BioNTech, AstraZeneca, Moderna, Novavax, and Johnson & Johnson, have been developed and are being distributed worldwide. Clinical trials for drug treatments such as remdesivir, dexamethasone, and monoclonal antibodies are underway and have shown promising results. 
  • 946
  • 11 Apr 2023
Topic Review
mRNA Vaccines against SARS-CoV-2
Coronaviruses are single-stranded positive-sense RNA (+ssRNA) viruses belonging to the Coronaviridae family. Their genome encodes replicase/transcriptase proteins, structural proteins and a set of non-structural proteins linked to their virulence and proofreading activities of the replicase complex. 
  • 1.1K
  • 06 Apr 2023
Topic Review
Tumor Necrosis Factor-Alpha (TNF-α) in COVID-19
The coronavirus disease 2019 (COVID-19) became a worldwide concern at the beginning of 2020 and has affected millions. High levels of proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukins are produced readily by innate immune cells to fight Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) infections. The presented work describes the potential of TNF-α in the prognosis, therapeutic and management of COVID-19.
  • 1.8K
  • 06 Apr 2023
Topic Review
COVID-19 Associated Pulmonary Thrombosis
Pulmonary thrombosis in situ is a pathological condition nonrelated to embolism from deep vein thrombosis (DVT) in the lower extremities. 
  • 823
  • 04 Apr 2023
Topic Review
The Pathophysiology of COVID-19 and T2DM Coagulopathy
Chronic inflammation and endothelium dysfunction are present in diabetic patients. COVID-19 has a high mortality rate in association with diabetes, partially due to the development of thromboembolic events in the context of coronavirus infection. Chronic inflammation, present in DM, enhances the synthesis of several cytokines. This chronic inflammatory state is preceded by a subclinical inflammatory response, represented by elevated IL-1β and IL-6 before the onset of type 2 diabetes mellitus (T2DM). Endothelial dysfunction is also a consequence of Diabetes mellitus (DM) and leads to micro- and macroangiopathy, and concomitantly to hypercoagulability.
  • 958
  • 03 Apr 2023
Topic Review
mRNA-Based COVID-19 Vaccines Using Lipid Nanoparticles
Lipid nanoparticles (LNPs) have recently emerged as one of the most advanced technologies for the highly efficient in vivo delivery of exogenous mRNA, particularly for COVID-19 vaccine delivery. LNPs comprise four different lipids: ionizable lipids, helper or neutral lipids, cholesterol, and lipids attached to polyethylene glycol (PEG). Since its first isolation in 1961, mRNA (that encodes the protein of interest) research has taken several paths, which made us understand its diversified functions and modification-mediated potential for therapeutic applications. As a result of the COVID-19 pandemic, nucleic acid therapeutics (NATs), particularly mRNA vaccines, potentials have been enabled for emerging infectious diseases. The translation of host genetic information (DNA) into proteins by ribosomes in the cytoplasm is mediated by mRNA.
  • 1.1K
  • 31 Mar 2023
Topic Review
Immunology of Multisystem Inflammatory Syndrome in Children
Immune responses following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in children are still under investigation. Even though coronavirus disease 2019 (COVID-19) is usually mild in the pediatric population, some children exhibit severe clinical manifestations, require hospitalization, or develop the most severe condition: a multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2 infection. The activated innate, humoral and T-cell-mediated immunological pathways that lead certain pediatric populations to present with MIS-C or remain asymptomatic after SARS-CoV-2 infection are yet to be established. This entry focuses on the immunological aspects of MIS-C with respect to innate, humoral, and cellular immunity. In addition, presents the role of the SARS-CoV-2 Spike protein as a superantigen in the pathophysiological mechanisms, discusses the great heterogeneity among the immunological studies in the pediatric population, and highlights possible reasons why some children with a certain genetic background present with MIS-C.
  • 1.1K
  • 31 Mar 2023
Topic Review
MicroRNA Let-7 in the Immunopathology of COVID-19
COVID-19 has presented itself as a challenging task to medical teams and researchers throughout the world, since the outbreak of SARS-CoV-2 started in the Chinese city of Wuhan. There are still new variants emerging, and the knowledge about the mechanisms used by the virus to infect cells and perpetuate itself are still not well understood. The scientific community is still trying to catch up with the velocity of new variants and, consequently, the new physiological pathways that appear along with it. It is known that the new coronavirus plays a role in changing many molecular pathways to take control of the infected cells. Many of these pathways are related to control genomic expression of certain genes by epigenetic ways, allowing the virus to modulate immune responses and cytokines production. The let-7 family of microRNAs, for instance, are known to promote increased viral fusion in the target cell through a mechanism involving the transmembrane serine protease 2 (TMPRSS2). It was also demonstrated they are able to increase the inflammatory activity through the NF-κB/IL-6/let-7/LIN-28 axis. 
  • 817
  • 30 Mar 2023
Topic Review
Immunology in the Acute Phase of COVID-19
COVID-19 is a viral disease that has caused millions of deaths around the world since 2020. Many strategies have been developed to manage patients in critical conditions; comprehension of the immune system is a key factor in viral clearance, tissue repairment, and adaptive immunity stimulus. Participation of immunity has been identified as a major factor, along with biomarkers, prediction of clinical outcomes, and antibody production after infection. Immune cells have been proposed not only as a hallmark of severity, but also as a predictor of clinical outcomes, while dynamics of inflammatory molecules can also induce worse consequences for acute patients.
  • 989
  • 29 Mar 2023
  • Page
  • of
  • 74

Other Entry Collections

>>